Legend Biotech logo

LEGN - Legend Biotech Share Price

$31.38 0.1  0.4%

Last Trade - 14/08/20

Large Cap
Market Cap £3.09bn
Enterprise Value £3.02bn
Revenue £45.0m
Position in Universe 1280th / 6381
Unlock LEGN Revenue
Relative Strength (%)
1m -20.4%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -27.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 23.6 49.1 57.3 +55.8%
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Legend Biotech Corp revenues increased 15% to $11.5M. Net loss increased from $12.4M to $44.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development expenses increase from $21.3M to $48M (expense), Finance costs increase from $38K to $4M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


LEGN Revenue Unlock LEGN Revenue

Net Income

LEGN Net Income Unlock LEGN Revenue

Normalised EPS

LEGN Normalised EPS Unlock LEGN Revenue

PE Ratio Range

LEGN PE Ratio Range Unlock LEGN Revenue

Dividend Yield Range

LEGN Dividend Yield Range Unlock LEGN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
LEGN EPS Forecasts Unlock LEGN Revenue
Profile Summary

Legend Biotech Corp is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, LCAR-B38M/JNJ-4528, is an autologous CAR-T cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in a number of hematologic malignancies including multiple myeloma (MM). The Company have a portfolio of earlier-stage autologous product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), Acute Myeloid Leukemia (AML), and T cell Lymphoma (TCL). It is also developing an allogeneic CAR-T product candidate targeting CD20 for the treatment of NHL. The Company also has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases.

Last Annual December 31st, 2019
Last Interim March 31st, 2020
No. of Shareholders: n/a
No. of Employees: 645
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 129,352,394
Free Float (0.0%)
Eligible for
LEGN Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for LEGN
Upcoming Events for LEGN
Frequently Asked Questions for Legend Biotech
What is the Legend Biotech share price?

As of 14/08/20, shares in Legend Biotech are trading at $31.38, giving the company a market capitalisation of £3.09bn. This share price information is delayed by 15 minutes.

How has the Legend Biotech share price performed this year?

Shares in Legend Biotech are currently trading at $31.38 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Legend Biotech price has moved by % over the past year.

What are the analyst and broker recommendations for Legend Biotech?

There are no analysts currently covering Legend Biotech.

When will Legend Biotech next release its financial results?

Legend Biotech is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Legend Biotech dividend yield?

Legend Biotech does not currently pay a dividend.

Does Legend Biotech pay a dividend?

Legend Biotech does not currently pay a dividend.

When does Legend Biotech next pay dividends?

Legend Biotech does not currently pay a dividend.

How do I buy Legend Biotech shares?

To buy shares in Legend Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Legend Biotech?

Shares in Legend Biotech are currently trading at $31.38, giving the company a market capitalisation of £3.09bn.

Where are Legend Biotech shares listed? Where are Legend Biotech shares listed?

Here are the trading details for Legend Biotech:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: LEGN
What kind of share is Legend Biotech?

Based on an overall assessment of its quality, value and momentum, Legend Biotech is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Legend Biotech share price forecast 2020?

We were not able to load any forecast data for Legend Biotech.

How can I tell whether the Legend Biotech share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Legend Biotech. Over the past six months, the relative strength of its shares against the market has been %. At the current price of $31.38, shares in Legend Biotech are trading at -15.29% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Legend Biotech PE Ratio?

We were not able to find PE ratio data for Legend Biotech.

Who are the key directors of Legend Biotech?

Legend Biotech's management team is headed by:

Xu Yuan - CEO
Frank Fan - CFD
Huang Ying - CFO
Meeta Chatterjee - SVP
Syed Rizvi - VPR
Corazon Sanders - DRC
Darren Ji - DRC
Philip Yau - DRC
Fangliang Zhang - CHM
Who are the major shareholders of Legend Biotech?

Here are the top five shareholders of Legend Biotech based on the size of their shareholding:

Hudson Bay Capital Management LP Hedge Fund
Percentage owned: 2.32% (3.06m shares)
Johnson & Johnson Innovation-JJDC, Inc. Venture Capital
Percentage owned: 1.23% (1.63m shares)
Matthews International Capital Management, L.L.C. Investment Advisor
Percentage owned: 0.91% (1.20m shares)
Capital Research Global Investors Investment Advisor
Percentage owned: 0.88% (1.16m shares)
American Funds SMALLCAP World Fund Mutual Fund
Percentage owned: 0.77% (1.02m shares)
Similar to LEGN
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.